Norris Medicines Share Price
Start SIP in Norris Medicines
Start SIPNorris Medicines Performance
Day Range
- Low 0
- High 0
52 Week Range
- Low 0
- High 0
- Open Price0
- Previous Close0
- Volume
Norris Medicines Investment Rating
-
Master Rating:
-
Norris Medicines has an operating revenue of Rs. 5.41 Cr. on a trailing 12-month basis. An annual revenue de-growth of -32% needs improvement, Pre-tax margin of -19% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 100 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.
Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 1 | 1 | 1 | 3 | 1 | 1 |
Operating Expenses Qtr Cr | 1 | 1 | 1 | 3 | 1 | 1 |
Operating Profit Qtr Cr | 0 | 0 | 0 | 0 | 0 | 1 |
Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 1 |
Net Profit Qtr Cr | 0 | 0 | 0 | 0 | -1 | -1 |
Norris Medicines Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹19.01
- 50 Day
- ₹17.81
- 100 Day
- ₹16.57
- 200 Day
- ₹15.54
- 20 Day
- ₹18.83
- 50 Day
- ₹18.08
- 100 Day
- ₹15.72
- 200 Day
- ₹15.95
Norris Medicines Resistance and Support
Resistance | |
---|---|
First Resistance | 22.84 |
Second Resistance | 22.85 |
Third Resistance | 22.85 |
RSI | 71.90 |
MFI | 81.29 |
MACD Single Line | 0.39 |
MACD | 0.87 |
Support | |
---|---|
First Support | 22.83 |
Second Support | 22.83 |
Third Supoort | 22.82 |
Norris Medicines Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 4,053 | 405,300 | 100 |
Week | 3,847 | 384,680 | 100 |
1 Month | 2,091 | 209,118 | 100 |
6 Month | 1,441 | 135,099 | 93.74 |
Norris Medicines Result Highlights
Norris Medicines Synopsis
BSE-Medical-Biomed/Biotech
Norris Medicines is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 8.36 Cr. and Equity Capital is Rs. 9.93 Cr. for the Year ended 31/03/2023. Norris Medicines Ltd. is a Public Limited Listed company incorporated on 07/09/1990 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1990PLC086581 and registration number is 086581.Market Cap | 23 |
Sales | 5 |
Shares in Float | 0.66 |
No of funds | 6 |
Yield |
Book Value | 7.63 |
U/D Vol ratio | 2.9 |
LTDebt / Equity | |
Alpha | 0.28 |
Beta | 0.38 |
Norris Medicines Shareholding Pattern
Owner Name | Sep-24 | Jun-24 | Mar-24 | Dec-23 |
---|---|---|---|---|
Promoters | 34.01% | 34.01% | 34.01% | 34.01% |
Mutual Funds | 0.01% | 0.01% | 0.01% | 0.01% |
Financial Institutions/ Banks | 0.06% | 0.06% | 0.06% | 0.06% |
Individual Investors | 20.71% | 20.7% | 20.7% | 20.66% |
Others | 45.21% | 45.22% | 45.22% | 45.26% |
Norris Medicines Management
Name | Designation |
---|---|
Mrs. Susmita Mahapatra | Woman Director |
Mr. Shaikh Amanullah Mohamed Azmathullah | Director |
Dr. Hiten Parikh | Director |
Mr. Vimal Shah | Managing Director |
Norris Medicines Forecast
Price Estimates
Norris Medicines Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-14 | Quarterly Results | |
2024-05-29 | Audited Results | |
2024-02-14 | Quarterly Results | |
2023-12-29 | Others | Inter alia : 1. To Consider and approve Authorized Signatory for Bank Operations. 2. To Consider and recommend Mr. Vimal Shah as a Director of the Company subject to Members approval. |
2023-11-18 | A.G.M. |
Norris Medicines FAQs
What is Share Price of Norris Medicines ?
Norris Medicines share price is ₹22 As on 10 November, 2024 | 00:45
What is the Market Cap of Norris Medicines ?
The Market Cap of Norris Medicines is ₹22.8 Cr As on 10 November, 2024 | 00:45
What is the P/E ratio of Norris Medicines ?
The P/E ratio of Norris Medicines is -24.3 As on 10 November, 2024 | 00:45
What is the PB ratio of Norris Medicines ?
The PB ratio of Norris Medicines is -1.7 As on 10 November, 2024 | 00:45
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.